ETX.L - e-Therapeutics plc
| Previous close | 3.8000 |
| Open | 3.8010 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 3.7750 - 4.0000 |
| 52-week range | 1.4000 - 7.9950 |
| Volume | 353,102 |
| Avg. volume | 7,111,644 |
| Market cap | 10.489M |
| Beta (3Y monthly) | -0.54 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.5000 |
| Earnings date | 5 Mar 2019 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 10.00 |
- Reuters - UK Focus
Suspended Woodford fund has sold around 100 mln pounds of assets
Neil Woodford has sold 97 million pounds ($123 million) of shares over the past 10 days to boost liquidity in his suspended equity income fund, a Woodford spokesman said on Thursday. Market participants have been expecting a wave of forced selling by Woodford, with some hedge funds taking out short positions against his investments. "Since suspension, Woodford has sold 97.1 million pounds of stock as he continues to reposition the Woodford Equity Income Fund portfolio," a Woodford spokesman said by email.
- EQS Group
Edison issues outlook on Jersey Electricity (JEL)
Edison Investment Research Limited 14-March-2019 / 12:38 GMT/BST * * *London, UK, 14 March 2019Edison issues outlook on Jersey Electricity (JEL)Jersey Electricity's (JEL) strong financial position and forecast cash flow should underpin 5% per year growth in the dividend per share. Although JEL faces wholesale cost rises, lower unit demand and a fluid regulatory situation, we believe that, given its strong position on pricing and service standards, it is well positioned to withstand these pressures. Our latest valuation analysis indicates increased upside potential from current levels.Our updated valuation (the average of peer group multiples, using cover-adjusted yield/DCF/SOTP), indicates a valuation of c 560p (+2.5%) versus 546p last year. In particular, the increased SOTP valuation (from 552p to 592p) has been driven by a growth in regulatory assets and reduced debt. Despite a recent rise in the share price following the better than expected FY18 results released in December 2018, the shares offer 20% upside to the average of our valuation, with the prospect of growing income from the dividend. Click here to view the full report.All reports published by Edison are available to download free of charge from its website www.edisoninvestmentresearch.comAbout Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.Edison is authorised and regulated by the Financial Conduct Authority.Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.For more information please contact Edison:Graeme Moyse, +44 (0)20 3077 5700 industrials@edisongroup.comLearn more at www.edisongroup.com and connect with Edison on: LinkedIn https://www.linkedin.com/company/edison-investment-research Twitter www.twitter.com/Edison_Inv_Res YouTube www.youtube.com/edisonitv * * *Dissemination of a CORPORATE NEWS, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. * * * End of Announcement - EQS News Service
- EQS Group
Edison issues update on e-Therapeutics (ETX)
Edison Investment Research Limited 05-March-2019 / 15:51 GMT/BST * * *London, UK, 5 March 2019Edison issues update on e-Therapeutics (ETX)e-Therapeutics' (ETX) FY19 results demonstrated continued financial prudence and its focus on partnering, out-licensing and non-dilutive financing. The FY19 operating loss was £5.1m, which is the same as our estimate. The cash outflow was £3.7m, resulting in a cash balance of £5.9m at the end of FY19. Both R&D and administrative expenses had been reduced from FY18 and the recently announced Novo collaboration generated £0.04m in FY19.We have updated our valuation to £69.4m or 26p/share, from £63.5m (24p/share), due to the impact of a stronger dollar on the dollar-based comparative transactions. All underlying assumptions remain unchanged. ETX expects more collaborations, and more visible transactions than the Novo collaboration and we would expect these to be incorporated into ETX's valuation when they occur. Click here to view the full report.All reports published by Edison are available to download free of charge from its website www.edisoninvestmentresearch.comAbout Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.Edison is authorised and regulated by the Financial Conduct Authority.Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.For more information please contact Edison:Andy Smith, +44 (0)20 3077 5700 healthcare@edisongroup.com Learn more at www.edisongroup.com and connect with Edison on: LinkedIn https://www.linkedin.com/company/edison-investment-research Twitter www.twitter.com/Edison_Inv_Res YouTube www.youtube.com/edisonitv * * *Dissemination of a CORPORATE NEWS, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. * * * End of Announcement - EQS News Service
- Simply Wall St.
Does Market Volatility Impact e-Therapeutics plc’s (LON:ETX) Share Price?
If you’re interested in e-Therapeutics plc (LON:ETX), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact Read More...
